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Myofascial pain syndrome (MPS) is a leading cause of chronic musculoskeletal pain.
However, its neurobiological mechanisms are not entirely elucidated. Given the complex
interaction between the networks involved in pain process, our approach, to providing
insights into the neural mechanisms of pain, was to investigate the relationship
between neurophysiological, neurochemical and clinical outcomes such as corticospinal
excitability. Recent evidence has demonstrated that three neural systems are affected
in chronic pain: (i) motor corticospinal system; (ii) internal descending pain modulation
system; and (iii) the system regulating neuroplasticity. In this cross-sectional study, we
aimed to examine the relationship between these three central systems in patients
with chronic MPS of whom do/do not respond to the Conditioned Pain Modulation
Task (CPM-task). The CPM-task was to immerse her non-dominant hand in cold water
(0−1◦C) to produce a heterotopic nociceptive stimulus. Corticospinal excitability was
the primary outcome; specifically, the motor evoked potential (MEP) and intracortical
facilitation (ICF) as assessed by transcranial magnetic stimulation (TMS). Secondary
outcomes were the cortical excitability parameters [current silent period (CSP) and short
intracortical inhibition (SICI)], serum brain-derived neurotrophic factor (BDNF), heat pain
threshold (HPT), and the disability related to pain (DRP). We included 33 women, (18–65
years old). The MANCOVA model using Bonferroni’s Multiple Comparison Test revealed
that non-responders (n = 10) compared to responders (n = 23) presented increased
intracortical facilitation (ICF; mean ± SD) 1.43 (0.3) vs. 1.11 (0.12), greater motor-evoked
potential amplitude (µV) 1.93 (0.54) vs. 1.40 (0.27), as well a higher serum BDNF (pg/Ml)
32.56 (9.95) vs. 25.59 (10.24), (P < 0.05 for all). Also, non-responders presented a
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higher level of DRP and decreased HPT (P < 0.05 for all). These findings suggest that
the loss of net descending pain inhibition was associated with an increase in ICF, serum
BDNF levels, and DRP. We propose a framework to explain the relationship and potential
directionality of these factors. In this framework we hypothesize that increased central
sensitization leads to a loss of descending pain inhibition that triggers compensatory
mechanisms as shown by increased motor cortical excitability.
Keywords: BNDF, cortical excitability, CPM, MEP, TMS, QST, chronic pain
INTRODUCTION
Myofascial pain syndrome (MPS) is a leading cause of
chronic musculoskeletal pain (Simons et al., 1999). MPS has
been associated with disability, and also with dysfunction of
corticospinal conduction as assessed by motor evoked potential
(MEP; Vidor et al., 2014). As with other chronic pain syndromes,
the mechanisms of MPS are not entirely elucidated. A major
barrier to the understanding of these mechanisms is that pain
is an experience orchestrated by a network of cortical regions,
elements of the limbic system and the spine-bulbospinal loop.
The ascending portion of this circuit involves the spine reticular
tract (Willer et al., 1999), which comprises modulatory systems
such as the opioidergic (Le Bars et al., 1981; Willer et al., 1990),
noradrenergic (Sanada et al., 2009; Makino et al., 2010), and
serotonergic systems (Chitour et al., 1982). Given this complex
interaction, our approach to provide insights into the neural
mechanisms of pain was to investigate the relationship between
neurophysiological, neurochemical, and clinical outcomes such
as corticospinal excitability as indexed by transcranial magnetic
stimulation (TMS) measurements, conditioned pain modulation
(CPM) to measure the descendent endogenous inhibitory pain
system and serum brain-derived neurotrophic factor (BDNF)
as a critical marker of neuroplasticity. Corticospinal excitability
as indexed by TMS has become a reliable marker in chronic
pain syndromes, including MPS (Vidor et al., 2014). It has
been shown that pain and disability are associated with an
imbalance between excitatory and inhibitory systems as assessed
by increased intracortical facilitation (ICF) and by a reduced
current silent period (CSP; Vidor et al., 2014; a proxy of
glutamatergic activity), a higher pain catastrophizing score (Volz
et al., 2013a) and a higher trait anxiety score (Vidor et al.,
2014).
The CPM (Yarnitsky, 2010) involves the diffuse noxious
inhibitory control (DNIC) system. The DNIC system assesses the
reduction in the pain sensation on the stimulus by a simultaneous
pain input from distant sites of the body (Le Bars, 2002). While
the CPM assesses how much, a conditioning stimulus can reduce
the pain response evoked by the other strong, painful stimuli
at a distant large body surface area (the test stimulus; Volz
et al., 2013a). When the CPM-task increases pain, this indicates
a disruption of endogenous pain-inhibitory processes and a
summation effect (King, 2014), which amplifies the pain response
and it is a process of the central sensitization (Boyer et al., 2014).
It appears that these pain-related neural changes maintain the
dysfunction of endogenous descending inhibitory mechanisms
as observed in many chronic pain syndromes including knee
osteoarthritis (Arendt-Nielsen et al., 2010), chronic pancreatitis
(Olesen et al., 2010), rheumatoid arthritis (Leﬄer et al., 2002a),
long-term trapezius myalgia (Leﬄer et al., 2002b), irritable
bowel syndrome (King et al., 2009), temporomandibular disorder
(King et al., 2009), fibromyalgia (Staud et al., 2003), and MPS
(Pielsticker et al., 2005).
BDNF, a critical molecule for the development and
maintenance of cortical neurons and cortical synapses,
interacts with the descendant modulatory system. Clinical
studies have found higher levels of BDNF in the blood (Deitos
et al., 2015) and cerebrospinal fluid in patients with chronic
pain (Bø et al., 2009), and in fibromyalgia has been associated
with a lower pain threshold (Zanette et al., 2014). This set of
evidence demonstrates that there are three main neural systems
involved in chronic pain: (i) the corticospinal motor system;
(ii) the internal descending pain modulation system; and (iii)
the system regulating neuroplasticity. Our hypothesis is that
disruption of the infra cortical medulator system, as assessed by
pain scores during the CPM-task, is correlated with dysfunction
of corticospinal conduction and disinhibition at the cortical
level, due to increases in the MEP amplitude, ICF, and serum
BDNF level. We aimed to analyze the relationship between these
three central systems in chronic MPS patients in responders and
non-responders to Quantitative Sensory Testing (QST) during
the immersion of her non-dominant hand in cold water (0−1◦C)
to produce a heterotopic nociceptive stimulus (CPM-task).
To determine the CPM we used the difference between the
pain score on NPS (0–10) QST during cold water immersion
(QST+CPM) at the temperature of the point at which subjects
felt 6/10 pain on the NPS scale [during the initial time period
(T0)]. Our primary outcomes were the MEP and ICF as assessed
by TMS. The secondary outcomes were the cortical excitability
parameters [current silent period (CSP) and short intracortical
inhibition (SICI)], serum BDNF level, heat pain threshold
(HPT), and the disability related to pain.
MATERIALS AND METHODS
This exploratory study was performed at the Hospital de Clinicas
de Porto Alegre in Porto Alegre, Brazil. The study protocol was
approved by the Institutional Review Board (IRB 0000921) at the
Hospital de Clinicas de Porto Alegre and conducted according
to the Declaration of Helsinki. All subjects provided written
informed consent for their participation. We administered
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clinical assessment scales validated in the Brazilian population.
Additionally, we collected behavioral measurements (i.e., several
pain assessments) and neurophysiological measurements (i.e.,
motor córtex excitability as indexed by TMS) to establish baseline
data.
Design Overview, Settings, and Participant
We recruited the participants from the general population
through public postings in different health care units and
physicians’ referrals from the Chronic Pain Service at the
Hospital de Clínicas de Porto Alegre. The inclusion criteria
included the following: (1) right-handed females (2) aged 19–
65 years old, (3) confirmed the diagnosis of MPS in the upper
body segment for at least 3 months before enrollment, and
(4) limitation in routine activities due to MPS. Furthermore,
patients needed to present with a pain score of the visual analog
scale (VAS) at least of 4 cm (i.e., moderate or severe pain;
Palos et al., 2006), associated with functional disability in most
days of the 3 months before enrollment. Disability associated
with MPS was evaluated using a questionnaire that included six
specific questions (yes/no). These questions aimed at assessing
interference with work, personal relationships, pleasure obtained
during activities, personal goals, clear thinking (i.e., problem
solving, concentrating, or remembering), and responsibilities
at home during the past 3 months. For enrollment, an
affirmative answer to one or more of these questions was
necessary to ensure that chronic pain was decreasing the
patient’s quality of life. Moreover, the diagnosis of MPS was
confirmed by a second experienced independent examiner with
significant clinical experience related to chronic pain. MPS
criteria were the presence of regional pain, normal neurological
examination, stiffness in the target muscles; decreased the
range of motion, the presence of palpable nodules, tender
points, trigger points, taut bands, and pain characterized as
hollow, dull, or deep that was exacerbated by stress. To
standardize the severity of MPS and to distinguish neuropathic
pain from ongoing nociception, were included only patients
with the Neuropathic Pain Diagnostic Questionnaire (DN4)
with a score equal to or higher than four (Bouhassira et al.,
2005). The presence of previous surgery on the affected
areas or other pain disorders such as rheumatoid arthritis,
radiculopathy, and fibromyalgia; and frequent use of steroidal
and non-steroidal anti-inflammatory medications were exclusion
criteria.
Anticipating an effect size (f) of 0.4 for a multiple regression
analysis allowing for two predictors and a type I and II errors of
0.05 and 0.20, respectively, and the minimum sample size was 30
patients. Finally, considering the likely attrition rate and other
unexpected factors, the required sample size was determined to
be 33 patients (Figure 1).
Instruments and Assessments
The tools used to assess psychological state were validated in
the Brazilian population (Staud et al., 2003; Kaipper et al.,
FIGURE 1 | The sequence of assessments.
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2010; Sehn et al., 2012; Caumo et al., 2013). Two independent
medical examiners that were blinded to the aim of the study
were trained to conduct the psychological tests and to administer
the pain scales. The patients’ baseline depressive symptoms
were assessed using the Beck Depression Inventory (BDI II;
Warmenhoven et al., 2012), and the Pittsburgh Sleep Quality
Index to assess the sleep quality (Buysse et al., 1989). To
measure the anxiety, we used the refined version of the State-
Trait Anxiety Inventory (STAI; Kaipper et al., 2010) obtained
using the Rasch model, which derivates shorter state-trait STAI-
Form X scales free of threshold disorders and for differential
item functioning (DIF) problems. The scores in the state- and
trait score ranges from 13 to 52, and 12 to 36, respectively.
The catastrophic thinking related to pain was assessed using
the Brazilian Portuguese Catastrophizing Scale (BP-PCS; Sehn
et al., 2012). To measure the pain intensity during the most
part of time in the last week was used the VAS, ranging
from 0 cm (no pain) to 10 cm (worst possible pain). We used
a standardized questionnaire to assess demographic data and
medical comorbidities.
As subjects with chronic pain usually use rescue analgesics
changes from week to week according to pain level, the analgesic
use was defined as the self-reported average used per week during
the last 3 months. For data analysis, we included the analgesic use
as a dichotomous variable: the analgesic was coded one when they
used more than 4 days per week while the analgesic uses less than
4 days per week it was coded as zero (reference value).
Outcomes
The primary outcomes were the MEP and ICF as assessed by
TMS. The secondary outcomes were the cortical excitability
parameters CSP and SICI, serum BDNF level, HPT, and the
disability related to pain assessed by Brazilian Profile of Chronic
Pain: Screen score (B-PCP:S). The primary factor of interest, the
score on NPS (0–10) during the conditioned pain modulated
(CPM-task), are described in detail below.
(a) The Brazilian Profile of Chronic Pain: Screen (B-PCP:S;
Caumo et al., 2013) was used for quick identification of an
individual’s multidimensional pain experience. The B-PCP:S
includes a severity scale (four items; possible score range of
0–32), an interference scale (six items; possible score range
of 0–36), and an emotional burden scale (five items; possible
score range of 0–25). The disability related to pain (DRP)
regarding severity, interference with daily activities, and the
emotional burden was evaluated using the B-PCP:S (Caumo
et al., 2013). It accepted as a criterion to define disability
a presence of chronic or recurrent pain or discomfort
causing restriction (Caumo et al., 2013); thus, we assumed
that higher scores on the B-PCP:S indicated more severe
disability or greater functional deficits at work, at home,
and during social situations and a higher emotional burden
(Vidor et al., 2014).
(b) To measure the cortical excitability parameters we used a
surface electromyography. The recordings were gathered
at the contralateral right first dorsal interosseous muscles
using Ag/AgCl electrodes. First, the resting motor threshold
(RMT) was determined by obtaining five motor evoked
potentials (MEPs) with a peak-to-peak amplitude of 50µV
from 10 consecutive trials. To define the MEP we recorded
10 MEPs with an intensity of 130% of the individual
RMT. Moreover, the cortical silent periods (CSPs) were
assessed during muscle activity by a dynamometer to
maintain them at ∼20% maximal force. Accordingly, the
CSPs were 10 records using an intensity of 130% of the RMT.
Short intracortical inhibition (SICI) using an inter-stimulus
interval of 2ms was also assessed. The conditioning stimulus
was set at 80% of the RMT while the test stimulus was set
at 100% of the individual MEP intensity. The intracortical
facilitation (ICF) was assessed with an inter-stimulus interval
of 12ms. We conducted the paired-pulse in a randomized
order for a total of 30 trials (ten each for ICF, SICI and
control stimuli). To calculate the RMT we used the lowest
stimulus intensity that was able to evoke an MEP of at least
50µV in 5 out of 10 consecutive trials. Off-line analyzes
included the collection of the duration of the CSPs as well
as the amplitudes of all of the MEPs, SICIs, and ICFs. The
corresponding units for these parameters included MEP in
µV, SICI, and ICF in their ratios to MEP and CSP in ms
(Pascual-Leone et al., 1994).
(c) The laboratory outcome measured was the serum level
of BDNF. We collected the blood samples before starting
the assessment. We centrifugate the blood samples for
10min at 4500 × g at 4◦C, and we stored the serum at
−80◦ C for the hormone assay. We determined the serum
BDNF using an Enzyme-Linked Immunosorbent Assay
(ELISA) using a ChemiKine BDNF Sandwich ELISA Kit,
CYT306 (Chemicon/Millipore, Billerica, MA, USA). The
lower detection limit of the kit for BDNF is 7.8 pg/mL.
(d) We used the Quantitative Sensory Testing (QST) to assess
HPT. This measure use themethod of limits with a computer
Peltier-based device thermode (30 × 30mm; Schestatsky
et al., 2011) attached to the skin on the ventral aspect of the
mid-forearm. The set at 32◦C and was increased at a rate of
1◦C/s to amaximum of 52◦C. The heat pain threshold (HPT)
of each patient was defined as the mean of three assessments
performed with an inter-stimuli interval of 40 s (Schestatsky
et al., 2011). The thermode position was slightly altered
between trials, to avoid, either sensitization or response
suppression of the cutaneous heat nociceptors.
(e) To measure the CPM-task we evaluated the pain intensity
in two tonics HPT test stimuli separated by a CPM-task.
We used the HPT as conditioning pain stimulus to elicit
a prolonged pain sensation to trigger CPM. The CPM-task
consisted of immersion of non-dominant hand in cold water
at a temperature of 0−1◦C for 1min. To maintain the water
temperature zero to 1◦Cwas used a thermostat to control the
temperature variation. The QST procedure was introduced
after 30 s of cold-water immersion. To determine the CPM
we used the difference between the pain score on NPS (0–
10) QST during cold water immersion (QST+CPM) at the
temperature of the point at which subjects felt 6/10 pain
on the NPS scale [during the initial time period (T0)]. An
accepted criterion to define responders to the CPM-task
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is the reduction of NPS pain scores under a heterotopic
stimulus comparedwithNPS pain scores under a nociceptive
stimulus without a heterotopic stimulus. If the patients did
not report a reduction or report an increase in their pain
score during the CPM-task, the descendent modulatory
systems were considered to have failed to modulate the
nociceptive response. For the data analysis, non-responders
showed a difference in the score on NPS, HPT1–HPT0, of
zero or higher, and for responders, these values were lower
than zero.
Statistical Analysis
Descriptive statistics were used to summarize the main socio-
demographic features of the sample. T-Tests for independent
samples and Chi-squared and Fisher’s exact tests were used to
compare continuous and categorical variables between groups
respectively. To test for normality was used the Shapiro-Wilk test.
To ensure that the data were normally distributed, we performed
a log transformation for BDNF level.
After verifying the corresponding assumptions, the Pearson
correlation coefficient (r) was used to assess the relationship
between covariates (age, sleep quality, catastrophic thinking
about pain; state-trait anxiety, and depressive symptoms) with
the outcomes related to cortical excitability parameters, BDNF,
and pain measures (see Table 3). To maintain the assumption of
independence between covariates and to control for collinearity
when the Pearson correlation coefficients (r) for two variables
were higher than 0.5 (moderate), in the multivariate analysis
model was included only one of the variables (see Table 4).
Based on this criterion the catastrophizing thinking related
to pain and trait-anxiety were included in the multivariate
analysis model, taking into account that they have been shown
to be correlated with cortical excitability in previous studies
on MPS (Volz et al., 2013b; Vidor et al., 2014) (Table 4).
The covariates not included in the multivariate analysis model
were age, depressive symptoms, sleep quality, and state-
anxiety. A multivariate covariance analysis (MANCOVA) model
was used to explore the relationship between the responders
and non-responders to multiple outcomes [cortical excitability
(MEP, ICI, ICF, CSP), BDNF, HPT, and disability related to
pain on B-PCP:S. Bonferroni’s Multiple Comparison Test was
used to identify the source of significant differences. The
data were analyzed using SPSS software version 22.0 (SPSS,
Chicago, IL).
RESULTS
Patient Characteristics
We screened 54 potential participants with a diagnosis of
MPS, and we included 33 in the study. The reasons for
exclusion were not fulfilling the diagnostic criteria for MPS,
not present a neuropathic component according to the DN4
(Neuropathic Pain Diagnostic Questionnaire), lacking disability
as defined in the protocol, and the presence of another
diagnosis (fibromyalgia). All enrolled subjects participated in
all aspects of the study and were included in all of analyses
(Table 1).
Univariate Analysis
Relationships between the Function of the
Corticospinal Modulatory System, Motor Córtex
Excitability, Pain Measures, and BDNF Level
Relationships between the function of the corticospinal
modulatory system, motor córtex excitability, pain measures,
and BDNF level according to a spectrum of responders and no
responder to CPM-task. The non-adjusted means and standard
deviation (SD) of the cortical excitability parameters, BDNF,
pain threshold and disability related to pain were presented in
Table 2.
Assessment of Relationship between Independent
Variables to Identify Potential Confounders
The Pearson correlation was used to identify potential
confounding factors in the relationships between outcomes
(cortical excitability, BDNF, HPT, and disability). The
correlated parameters were the scores of the Brazilian
Portuguese Catastrophizing Scale (B-PCS); Beck Depression
Inventory (BDI); Pittsburgh Sleep Quality Index (PSQI); and
Short State-Trait Anxiety Inventory (STAI-E-T), and age
(Table 3). The covariates included in the multivariate analysis
model (Table 4) were the trait-anxiety and catastrophizing
scores.
Multivariate Analysis of the Relationship
between the Corticospinal Modulatory
System, Cortical Excitability, BDNF, HPT,
and Disability According to Spectrum of
Responders and Non-Responders to
CPM-task
The results of the MANCOVA model analysis with multiple
outcomes as dependent variables, including cortical excitability
parameters (MEP, ICF, SICI, CSP), BDNF, HPT, and disability
related to pain according to spectrum of responders and
non-responders to CPM-task, and the STAI-E-T score and
catastrophizing score, as independent variables, are presented
in Table 4. The MANCOVA model using Bonferroni’s Multiple
Comparison Test revealed a significant relationship between
the responders and non-responders groups and the outcomes
related to cortical excitability measurements (ICF and MEP),
BDNF, disability related to pain and HPT [Hotelling’s Trace
= 1.84, F(34) = 6.05, P < 0.001]. This analysis presented
a power of 0.99. The adjusted determination coefficient of
this model was R2 = 0.57; thus, the variables included
in the model explain 57% of the variance in the outcome
variables. The results of this adjusted multivariate model are
presented in Table 4. Non-responders showed higher cortical
excitability (ICF, MEP), greater disability related to pain, higher
BDNF level, and lower HPT. However, no effect was observed
in other cortical excitability parameters (CSP and ICI; see
Table 4).
In Figures 2A–C are presented the relationships according
to a spectrum of responders and non-responders to CPM-task
and intracortical facilitation and MEP (primary outcomes) and
BDNF (secondary outcome). The means were compared using
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TABLE 1 | Demographic and clinical characteristics of the study sample.
Variables Non responders (n = 23) Responders (n = 10) P
Age (years) 43.36 (14.78) 48.30 (9.13) 0.33
Marital status (married/unmarried) 13/10 4/6 0.31
Education (years) 13.91 (4.25) 12.57 (3.88) 0.37
Smoking (yes/no) 1/22 0/10 0.69
Alcohol consumption (yes/no) 22/1 10/0 0.69
Duration of pain (years) 6.04 (1.64) 6.4 (0.97) 0.42
Pain on visual analog scale (cm) 8 (1.33) 6.5 (1.85) 0.01
Trait-anxiety (STAI-T) 28.82 (6.14) 25.17 (6.41) 0.13
State-anxiety (STA-T) 30.0 (8.42) 29.91 (5.75) 0.98
Beck depression inventory 13.45 (7.04) 15.83 (7.12) 0.37
Brazilian Portuguese Catastrophizing Scale (BP-PCS) 33.82 (6.98) 31.52 (8.14) 0.42
Number of days analgesics were used per week in the last 3 months (<4 times/= 4 times)a 8/15 2/8 0.33
Presence of other chronic diseases before appearance of pain (yes/no)b 4/19 2/8 0.6
Diagnosis of psychiatric disorders (yes/no) 8/15 5/5 0.32
Active use of central nervous system medication (yes/no)c 20/3 7/3 0.25
Values are given as the mean (SD) or frequency (n = 33).
aThe same patient may have used more than one medication.
bChronic diseases other than pain: hypertension (n = 12); ischemic heart disease (n = 1); heart attack (n = 1); diabetes mellitus (n = 5); thyroid diseases (n = 2); other chronic diseases
listed (n = 0).
cCentral nervous medication: tricyclic antidepressant (n = 2); topiromate (n = 1); tylex (n = 1).
TABLE 2 | Measurements of motor córtex parameters by TMS, HPT, B-PCP:S, and BDNF (n = 33).
Cortical Excitability Measures Non-responders (n = 23) Responders (n = 10) P&
Mean ± SD Median (Q25, Q75) Mean ± SD Median (Q25, Q75)
Motor threshold (MT) 44.46 (8.04) 44 (32: 65) 41.1 (5.53) 40.5 (32; 50) 0.15
Motor evoked potential (mV) 1. 93 (0.54) 2.06 (0.98; 3.14) 1.40 (0.27) 1.42 (1.03); 1.81) 0.01
Intracortical facilitation (ratio: ICF/ test stimulus) 1.43 (0.3) 1.35 (0.71; 1.99) 1.11 (0.12) 1.09 (0.94; 1.24) 0.00
Short interval intracortical inhibition (ratio: SICI/ test stimulus) 0.25 (0.02) 0.25 (0.23;0.27) 0.27 (0.10) 0.25 (0.08; 0.42) 0.38
Cortical silent period (CSP) 69.36 (21.74) 79.00 (38.0;120.0) 61.91 (15.49) 62.50 (33.25; 91.75) 0.17
Profile of chronic pain: screen for Brazilian population (B-PCP:S) 71.00 (10.02) 73.00 (55.0;91. 0) 59.22 (11.23) 63.00 (51.0; 75.0) 0.00
Quantitative sensory testing (◦C) 42.78 (4.27) 44 (35;50) 38.0 (3.03) 38.00 (37: 41) 0.00
Brain-derived neurotrophic factor (BDNF) pg/ml (log) 32.56 (9.95) 33.0 (20.0;36. 0) 25.59 (10.24) 22.5 (5.5; 39.5) 0.02
Motor evoked potential: (MEP); Interquartile interval (Q). Intra-cortical inhibition (ICI) expresses the relationship between the amplitude of wave and motor evoked potentials (relative
amplitude, express in %), at inter-stimuli intervals (ISIs) of 2ms with paired-pulse. The first is a sub-threshold stimulus [80% of the rest motor threshold (rMT)] followed by the second
one which is a suprathreshold stimulus (130% rMT).
(A) Cortical silent period (CSP) expressed in milliseconds (ms);
(B) Motor-evoked potentials (MEP) expressed inmV, evoked by a stimulus of 130% the intensity of the rMT, and should have peak-to-peak MEP amplitude of at least 1mV.
&, Comparisons of mean using t-test for independent samples.
MANCOVA with Bonferroni’s Multiple Comparison test (the
model was shown in Figures 2A–C; Table 4).
DISCUSSION
This study confirmed our hypothesis that the descending pain
modulation system as assessed according to a spectrum of
responders and non-responders to CPM-task is simultaneously
correlated with a disinhibition at the cortical level, as measured
by ICF and with global neuroplasticity levels as determined
by serum BDNF. Also, the disengagement of descending pain
modulatory system was correlated with a dysfunction of the
corticospinal pathway as indexed by MEP, a lower HPT, and a
greater disability.
The current study expanded on the data available in the
literature showing that the magnitude of disinhibition in
regulating sensory information was associated with changes in
the cortical and subcortical levels. This disinhibition state occurs
through multiple neurobiological systems, which can amplify
sensory pain signals to the neural pain matrix. Additionally,
the level disengagement of descending pain modulatory system
was correlated with changes in serum BDNF level, which is
involved in the modulation of the excitatory/inhibitory central
nervous system balance. Thus, the variation in the spectrum
of dysfunction of internal modulator system in chronic pain
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TABLE 3 | Pearson correlation coefficient (r) between potential confounding factors and outcomes (n = 33).
Age STAI-T STAI-E BPC-S B-PCP:S BDI PSQI MEP ICF SICI CSP BDNF
Age r = 0.05
STAI-T r = 001 r = 0.15
STAI-E r = −0.04 r = 0.65** r = –0.07
BP-PCS r = 0.06 r = 0.32 r = 0.29 r = –0.08
B-PCP:S r = −0.13 r = 0.40* r = 0.19 r = 0.62** r = –0.11
BDI r = 0.18 r = 0.58** r = 0.43** r = 0.66** r = 0.54** r = –0.25
PSQI r = −0.07 r = 0.34* r = 0.24 r = 0.54** r = 0.36* r = 0.46** r = –0.11
MEP r = −0.26 r = 0.05 r = −0.08 0.11 r = 0.26 r = −0.10 r = −0.05 r = 0.33*
ICF r = −0.01 r = 0.15 r = −0.06 0.14 r = 0.45** r = 0.09 r = −0.07 r = 042* r = 0.25
SICI r = −0.13 r = −0.12 r = −0.27 –0.01 r = −0.03 r = −0.03 r = −0.06 r = −0.15 r = 0.04 r = −0.27
CSP r = −0.05 r = −0.14 r = 0.05 –0.18 r = −0.13 r = −0.13 r = −0.21 r = 0.01 r = 0.27 r = 0.18 –0.38*
HPT r = 0.32 r = 0.03 r = −0.08 0.28 r = 0.07 r = 0.20 r = 0.11 r = −0.35* r = −0.05 r = 0.34* r = −0.11 r = 0.20
**Correlation is significant at the 0.01 level (2-tailed). *Correlation is significant at the 0.05 level (2-tailed). Brazilian Portuguese Catastrophizing Scale (BP-PCS); Beck Depression Inventory
(BDI); Pittsburgh Sleep Quality Index (PSQI); Short State-Trait Anxiety Inventory (STAI-E-T); Brazilian Profile of Chronic Pain: Screen (B-PCP:S); Intra-cortical inhibition (ICI); Cortical silent
period (CSP): Motor-evoked potentials (MEP) expressed inmV, Brain-derived neurotrophic factor (BDNF) pg/ml (log).
conditions could be understood as a signal from a balance in
the neuroplasticity mediators involved in the modulation of the
excitatory/inhibitory central nervous system (CNS; Deitos et al.,
2015). While that the variation of BDNF could be interpreted
as a signal from a “diseased balance,” once such balance differs
between the spectrum of responders and responders to CPM-
task. However, persists the concerns how good is this signal to
identify the chronic pain imbalance in the CNS and how is its
predictive properties for the evaluation of the MPS.
These results demonstrated that this integrative pattern to
assess changes in the pain pathway highlights that a cross
talk between the neural network of cortical regions and
the spine-bulbospinal loop occurs along with changes in the
BDNF secretion, which is the central marker of neuroplasticity
process mechanisms. Thus, this set of changes reinforcing the
hypothesis, that, if we improve the understanding of underlying
neurophysiological mechanisms of chronic MPS, this could give
support for the clinical decision based on practical approaches
for its recognition (Nijs et al., 2010). Additionally, these findings
provide some theoretical support for the mechanism involved
in the effect of interventions that improved pain and enhanced
the function of the descendent modulatory system in studies
that used melatonin, amitriptyline (de Zanette et al., 2014),
rTMS (Dall’Agnol et al., 2014), and the combination treatment
of CPM and duloxetine (Yarnitsky et al., 2012). Although
human studies permit us to determine only the effect in the
network, our findings allow a new way to construct the rational
to combine therapeutic approaches to improve functional
of descending pain modulatory systems. Such techniques
include pharmacological (i.e., antidepressant, anticonvulsant,
etc.) and non-pharmacological approaches (i.e., Transcranial
direct current stimulation (tDCS), TMS, electroacupuncture and
other physical therapy).
We observed greater MEPs amplitude in non-responders
to CPM-task (Table 4). Although a significant portion of the
corticospinal input to the motoneuron pool is relay via lumbar
group II interneurons (Marchand-Pauvert et al., 1999), the MEP
amplitude is a reflection of the latency of depolarization of the
spinal motor neuron pool. Its amplitude reflects the integrity
and function of conduction along the efferent pathway, which
form part of the lumbar propriospinal system and it express
the excitability of the cortical and spinal motor neuron pool
(Marchand-Pauvert et al., 1999; Pierrot-Deseilligny and Burke,
2005; Iglesias et al., 2008). Thereby, this result suggests that an
enhanced activity of descending tracts, whose motor portion is
assessed by the MEP, suggests that the inhibitory capacity of the
corticospinal modulator system is reduced (Vidor et al., 2014),
resulting in increased amplitude of MEP. One critical issue here
is whether corticospinal excitability is a compensatory or a causal
mechanism of pain. Given our data does not allow us to clarify
the temporal relationship between these two variables; we can
only hypothesize the correlation between these two variables
(MEP and CPM response). We have proposed before that
increasedmotor cortex excitability is a compensatorymechanism
aiming to reduce thalamic overactivity and thus pain (Castillo
Saavedra et al., 2014); though this mechanism is not enough
to control pain (an anology here would be increased insulin
in a subject with hyperglycemia; increased insulin levels would
be the compensatory mechanism). Therefore, increased pain
increases corticospinal excitability and when pain is controlled
this marker becomes normalized. The data from ICF supports
this hypothesis. We have proposed before that increased motor
cortex excitability is a compensatory mechanism aiming to
reduce thalamic overactivity and thus pain (Castillo Saavedra
et al., 2014).
Either increased ICF or decreased ICI suggest an
involvement of cortical mechanisms in the dysfunction
of the descendent modulatory system, which facilitate the
activity of the corticospinal system. Although the ICF is a
complex phenomenon, it reflects increase in the activity within
glutamatergic circuits, it also may arise through a loss of
GABA-A-mediated modulation (Di Lazzaro et al., 2000; Fedi
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TABLE 4 | Relationship between outcomes (cortical excitability parameters, pain measures and BDNF), and responders and no responders according
change in NPS (0–10) during the CPM-task (n = 33).
Dependent variable Type III Sum of Squares df Mean Square F P Partial eta Squared
Motor evoked potential (mV) 1.15 3 0.38 2.79 0.03 0.22
Intracortical facilitation (ratio: ICF/ test stimulus) 2.52 3 0.84 5.81 0.00 0.38
Short intracortical inhibition (ratio: SICI/test stimulus) 0.94 3 0.31 9.19 0.00 0.49
Cortical silent period 0.004 3 0.001 0.17 0.91 0.01
Brazilian profile of chronic pain: screen (B-PCP:S) 929.06 3 309.69 1.10 0.36 0.10
Quantitative sensory testing (◦C) 184.73 3 61.58 4.86 0.00 0.33
Brain-derived neurotrophic factor (BDNF) pg/ml (log) 2881.96 3 960.65 15.40 0.00 0.61
Parameter SEM βa t P
MOTOR EVOKED POTENTIAL (mV)
Conditioned pain modulation (CPM) during CPM/task
No respondera 0.61 0.15 4.09 0.00*
Brazilian Portuguese catastrophizing scale (BP-PCS) 0.007 0.009 0.74 0.46
State-anxiety (STAI-T) −0.01 0.01 −1.50 0.14
INTRACORTICAL FACILITATION (RATIO: ICF/ TEST STIMULUS)
Conditioned pain modulation (CPM) during CPM/task 0.33 0.07 4.50 0.00*
No respondera
Brazilian Portuguese catastrophizing scale (BP-PCS) 0.004 0.004 0.88 0.38
State-anxiety (STAI-T) 0.004 0.006 0.70 0.48
SHORT INTRACORTICAL INHIBITION (RATIO: SICI/TEST STIMULUS)
Conditioned pain modulation (CPM) during CPM/task −0.02 0.03 −0.62 0.54
No responder a
Brazilian Portuguese catastrophizing scale (BP-PCS) −0.01 0.02 −0.34 0.80
State-anxiety (STAI-T) 1.85 0.003 0.007 0.99
CORTICAL SILENT PERIOD
Conditioned pain modulation (CPM) during CPM/task 10.82 6.66 1.62 0.11
No respondera
Brazilian Portuguese catastrophizing scale (BP-PCS) −0.19 0.40 −0.47 0.64
State-anxiety (STAI-T) −0.47 0.50 −0.94 0.36
BRAZILIAN PROFILE OF CHRONIC PAIN: SCREEN (B-PCP:S)
Conditioned pain modulation (CPM) during CPM/task 7.81 3.13 2.48 0.01*
No respondera
Brazilian Portuguese catastrophizing scale (BP-PCS) 0.80 0.18 4.24 0.00*
State-anxiety (STAI-T) 0.51 0.24 2.17 0.03*
QUANTITATIVE SENSORY TESTING (◦C)
Conditioned pain modulation (CPM) during CPM/task −3.82 1.41 −2.70 0.01*
No respondera
Brazilian Portuguese catastrophizing scale (BP-PCS) 0.08 0.08 0.99 0.33
State-anxiety (STAI-T) −0.19 0.10 −1.82 0.07
BRAIN-DERIVED NEUROTROPHIC FACTOR (BDNF) PG/ML (log)
Conditioned pain modulation (CPM) during CPM/task 0.39 0.14 2.66 0.01*
No respondera
Brazilian Portuguese catastrophizing scale (BP-PCS) −0.05 0.09 −0.61 0.54
State-anxiety (STAI-T) −0.01 0.01 −1.47 0.15
aReference category is no responder, hence a positive value mean that the mean was higher in no responder.
CPM-task [no responder (NPS (0–10) HPT1–HPT0 ≥ 0) or responder (NPS (0–10) HPT1–HPT0 <0] *P < 0.05.
et al., 2008). Additionally, the disinhibition involves the loss of
inhibitory pyramidal cells. MEP amplitude is also an indicator
of primary motor córtex excitability: larger amplitudes indicate
higher excitability of the motor córtex, which may modulate
intracortical excitability and the transmission efficiency of
corticospinal neurons, resulting in less facilitation. Overall,
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FIGURE 2 | Comparisons between [non-responders (NPS (0–10)
HPT1–HPT0 ≥ 0; n = 10) and responders (NPS (0–10) HPT1–HPT0 < 0;
n = 23)]. (A) Motor evoked potential (mV); (B) Intra-cortical facilitation
(Continued)
FIGURE 2 | Continued
(amplitude/MEP amplitude ratio = ICF); and (C) Brain derived neurotrophic
factor (BDNF) ng/ml (Log). Error bars indicate standard error of the mean
(S.E.M.). Asterisks positioned above the bars indicate differences between
groups (responders and non-responders to CPM-task) assessed by
MANCOVA with post-hoc Bonferroni’s Multiple Comparison test.
as proposed above these changes in cortical plasticity could
be explained as a compensatory mechanism to downregulate
increased excitability in the pain neural networks such as
thalamic structures.
The higher serum BDNF in non-responders suggests that
this neurotrophin may be a marker of severity of CS. The
CS involves a proliferation of synaptic activity due the trophic
factors, to support maladaptive plasticity that perpetuates the
sensation of pain. Our findings give neurophysiological support
(MEP) to understand the link between serum BDNF and the
severity of dysfunction of the descendent modulatory system.
Even though this relationship is complex, they support the idea
that the activity of the descending inhibitory system is related
to central sensitization (Schwenkreis et al., 2003; Deitos et al.,
2015) and a greater activation in the brainstem (Graven-Nielsen
et al., 2012). This assumption, supported by an experimental
study with rats exposed to chronic pain, demonstrates that
the BDNF effect on pain pathways may change according to
the region of central nervous system (i.e., spine, brainstem,
hippocampus, and cortex, etc.; Spezia Adachi et al., 2015).
The mentioned study demonstrated that the tDCS decreased
the BDNF levels in the spinal cord and brainstem, whereas
BDNF levels did not change in the hippocampus (Spezia Adachi
et al., 2015). These differents effects according to site suggest
that BDNF activates distinct pathways (i.e., descending systems)
and that its effect is pleiotropic. Although previous findings
show that the increase in excitatory activity and the decrease
in inhibitory synaptic activity in the córtex related to BNDF
level (Ren and Dubner, 2007; Tao et al., 2014), the present
results do not allow for a conclusion regarding a cause-effect
relationship between BDNF level and descendent modulatory
system dysfunction.
Overall, the findings of this study corroborate the idea that
the BDNF modulates the synaptic plasticity in an activity-
dependent manner to strengthen a nociceptive transmission,
recruits non-nociceptive input to the pain pathways and it
binds to high-affinity trkB receptors. This BDNF effect enhances
the response that NMDA-mediated C-fibers evoke, which
in turn causes activation of several signaling pathways in
spinothalamic tract neurons. Thereby, this strength excitatory
synapsis promotes the disinhibition of descending pathways
(Zanette et al., 2014). This statement is also supported
indirectly by clinical findings, where the serum BDNF was
correlated inversely with the pressure pain threshold in
fibromyalgia (Zanette et al., 2014). Equally, we showed that the
BDNF increase would be favoring pain transmission because
greater scores in the CPM indicates a lower function in the
descending pain modulatory system and a higher propensity
for pain. This finding is biologically plausible because the
enhance in the BDNF activates signaling pathways in the
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spinothalamic tract, which reduces the GABAergic inhibitory
effect (Spezia Adachi et al., 2015). These findings support the
hypothesis that the chronic pain induces reorganization in
circuits involved in pain processing at cortical and in descending
pain modulatory system. Although the relationship between
BDNF with the physiopathology of pain is complex, it has
important functions in the processes of neurogenesis and
neuroplasticity. Thereby, efforts are being made to understand its
role in the pain modulatory system.
In the current study, a lower HPT and higher DRP in
non-responders were observed (Table 4). These results are
congruent with evidence from previous studies that a lower
pain threshold in patients with long-term chronic pain may be
a signal of lack of function of the inhibitory system (Kwon
et al., 2013; Defrin et al., 2015). Another explanation for this
finding is a potential protective effect if one considers that the
hippocampus amplifies signals to the neural representation (Ma
et al., 2012).
A greater disability according to scores on the B-PCP:S
was associated with the disinhibition of the descendent pain
modulatory system. The B-PCP:S dominions indicate pain
severity, restriction for daily activities (at work, at home, during
social situations) and the emotional burden. According to a
spectrum of responder and non-responders to CPM-task, the
disability was correlated positively with the catastrophizing
and trait-anxiety. In previous study we demonstrated the
relationship between greater disability related to pain and a
higher trait anxiety in MPS (Vidor et al., 2014). While in
another study with healthy subjects was observed that the
perceived intensity of the conditioning stimulus was associated
with the pain catastrophizing and trait anxiety (King, 2014).
In fact, the current findings suggest that the relationship
between the descending modulatory system and the disability
related to pain is regulated by brain regions that are involved
not only with pain but also with cognitive and emotional
functioning in general (Pessoa, 2008). Similar dysfunction was
observed when there were lesions in brain regions implicated
in descending pain modulation (i.e., traumatic brain injury
and multiple sclerosis), including the medial prefrontal córtex
(PFC) and rostral anterior cingulate córtex (ACC; Bushnell
et al., 2013). Additionally, it has been demonstrated that the
alterations in the biological integrity and functioning of brain
regions were involved in both pain control and cognitive and
emotional functioning. Thereby, the changes in this network
could explain the relationship between the severity disability
and the dysfunction of the corticospinal pain modulatory system
(Table 4).
This study had some limitations: Firstly, TMS is an
indirect neurophysiological evaluation of neurotransmitter
system activity. Secondly, only females were evaluated, as
gender differences in pain perception and modulation are
controversial. Thirdly, psychiatric disorders are a potential
confounding factor in chronic pain syndromes, and they cannot
have been adequately controlled. The psychiatric symptoms
(anxiety, depression, catastrophizing, and psychiatric diagnosis)
were equally distributed between the groups (responder vs.
non-responder). In fact, 39.39% (14/33) of patients suffered
from mental illnesses. However, this finding is expected, because
the emotional disturbance is part of chronic pain syndromes,
and they can worsen the sensitization and chronification.
Moreover, the results of this study need to be carefully
interpreted because it was an exploratory study. Further,
research on chronic pain of different psychopathologies is
required to confirm our initial findings and the impact of
our findings on patients’ responses to different therapeutic
approaches.
These results suggest that a non-response to the CPM-task is
likely due to increased plasticity to in central structures associated
with pain that control endogenous inhibitory control and that
in this case compensatory mechanisms are activated as reflected
by increased cortical excitability. This failure to respond to
CPM-task is associated with higher serum BDNF, lower HPT,
and a greater level of disability related to pain. Overall, these
findings suggest that the CPM-task is a test that allows for
inference regarding the loss of net descending pain inhibition.
Thus, this short and simple test might be useful for predicting
a patient’s response to therapy, and it helps in the clinical
decision-making process for individual patients. The results of
this study may also assist in the development of individualized
treatment.
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